science

Ropeginterferon alfa-2b

Ropeginterferon alfa-2b is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Ropeginterferon alfa-2b rather than just read about it. In short: Ropeginterferon alfa-2b, sold under the brand name Besremi, is a medication used to treat polycythemia vera and essential thrombocythemia. It is an interferon.

Key takeaways

Ropeginterferon alfa-2b belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Ropeginterferon alfa-2b to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Ropeginterferon alfa-2b from memory before moving on to harder problems.

Reference excerpt

Ropeginterferon alfa-2b, sold under the brand name Besremi, is a medication used to treat polycythemia vera and essential thrombocythemia. It is an interferon. It is given by injection. The most common side effects include low levels of white blood cells and platelets (blood components that help the blood to clot), muscle and joint pain, tiredness, flu-like symptoms and increased blood levels of gamma-glutamyl transferase (a sign of liver problems). Ropeginterferon alfa-2b can cause liver enzyme elevations, low levels of white blood cells, low levels of platelets, joint pain, fatigue, itching, upper airway infection, muscle pain and flu-like illness. Side effects may also include urinary tract infection, depression and transient ischemic attacks (stroke-like attacks). It was approved for medical use in the European Union in February 2019, and in the United States in November 2021. Ropeginterferon alfa-2b is the first medication approved by the US Food and Drug Administration (FDA) to treat polycythemia vera that people can take regardless of their treatment history, and the first interferon therapy specifically approved for polycythemia vera. The FDA considers it to be a first-in-class medication.

Medical uses In the European Union, ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythemia vera without symptomatic splenomegaly. In the United States it is indicated for the treatment of polycythemia vera. Ropeginterferon alfa-2b showed promising clinical activities in the treatment of moderate COVID-19.

History The effectiveness and safety of ropeginterferon alfa-2b were evaluated in a multicenter, single-arm trial that lasted 7.5 years. In this trial, 51 adults with polycythemia vera received ropeginterferon alfa-2b for an average of about five years. The effectiveness of ropeginterferon alfa-2b was assessed by looking at how many participants achieved complete hematological response, which meant that participants had a red blood cell volume of less than 45% without a recent phlebotomy, normal white cell counts and platelet counts, a normal spleen size, and no blood clots. Overall, 61% of participants had a complete hematological response. Participants received the highest administered dose tolerated every two weeks subcutaneously. The starting dose was lower for participants who were transitioning from hydroxyurea. The trial was conducted at six sites exclusively in Austria. The safety of ropeginterferon alfa-2b was based primarily on findings from the efficacy study in 51 participants. Two additional studies served as supportive safety data; therefore, the number of participants representing efficacy findings may differ from the number of participants representing safety findings due to different pools of study participants analyzed for efficacy and safety. The US Food and Drug Administration (FDA) granted the application for ropeginterferon alfa-2b orphan drug designation and granted the approval of Besremi to PharmaEssentia Corporation.

References

External links "Ropeginterferon alfa-2B". NCI Drug Dictionary. National Cancer Institute. "Ropeginterferon Alfa-2b-njft". National Cancer Institute. 21 June 2021. Clinical trial number NCT01193699 for "Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)" at ClinicalTrials.gov Clinical trial number NCT02218047 for "AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Ropeginterferon alfa-2b

Start with the simplest possible case. Write down what Ropeginterferon alfa-2b claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Ropeginterferon alfa-2b before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Ropeginterferon alfa-2b ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Ropeginterferon alfa-2b

In research: Ropeginterferon alfa-2b appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Ropeginterferon alfa-2b in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Ropeginterferon alfa-2b is common in secondary-school and first-year university syllabi. It links to neighbouring topics Immunostimulants, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Ropeginterferon alfa-2b outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Ropeginterferon alfa-2b” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Ropeginterferon alfa-2b in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Ropeginterferon alfa-2b means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Ropeginterferon alfa-2b out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Ropeginterferon alfa-2b in simple terms?

Ropeginterferon alfa-2b, sold under the brand name Besremi, is a medication used to treat polycythemia vera and essential thrombocythemia. It is an interferon.

Why does Ropeginterferon alfa-2b matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Ropeginterferon alfa-2b?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Ropeginterferon alfa-2b.